2seventy bio
TSVT
TSVT was delisted on the 13th of May, 2025.
141 hedge funds and large institutions have $317M invested in 2seventy bio in 2022 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 40 increasing their positions, 32 reducing their positions, and 19 closing their positions.
148% more call options, than puts
Call options by funds: $500K | Put options by funds: $202K
53% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 19
25% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 32
5% more funds holding
Funds holding: 134 → 141 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
36% less capital invested
Capital invested by funds: $494M → $317M (-$176M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$17.4M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$9.34M |
| 3 |
Millennium Management
New York
|
+$8.45M |
| 4 |
BlackRock
New York
|
+$5.99M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$18.4M |
| 2 |
RI
RTW Investments
New York
|
-$17.9M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$16.9M |
| 4 |
SC
Sessa Capital
New York
|
-$4.45M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$4.1M |
TSVT Hedge Fund Activity: Q4 2022 in Review
141 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in 2seventy bio (TSVT) for Q4 2022, worth a combined $317M — down 36% from $494M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new TSVT positions and 19 closed out — a net gain of 10 holders — while 40 added to existing stakes and 32 trimmed.
The largest buyer was Casdin Capital, adding an estimated $17.4M. The largest seller was Armistice Capital, exiting entirely with an estimated $18.4M sold.
- 141 institutional investors held 2seventy bio (TSVT) as of Q4 2022, up from 134 in Q3 2022.
- Funds reported $317M of 2seventy bio stock for Q4 2022, down 36% quarter-over-quarter.
- 29 funds opened new 2seventy bio positions in Q4 2022 and 19 closed out, a net change of +10 holders.
- The largest 2seventy bio buyer in Q4 2022 was Casdin Capital, an estimated $17.4M added.
- The largest 2seventy bio seller in Q4 2022 was Armistice Capital, an estimated $18.4M sold.
Based on aggregated 13F filings for Q4 2022.